Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121516 | 0.82 | PLG (0.42) | SLC18A3SIGMAR1PLGP2RY14 | |
| SCHEMBL7121523 | 0.82 | PLG (0.42) | SLC18A3SIGMAR1PLGP2RY14 | |
| SCHEMBL7121518 | 0.82 | PLG (0.42) | SLC18A3SIGMAR1PLGP2RY14 | |
| SCHEMBL15730577 | 0.82 | HDAC2 (0.45) | SLC18A3SIGMAR1AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL4194401 | 0.82 | HDAC2 (0.45) | SLC18A3SIGMAR1AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL4207545 | 0.82 | HDAC2 (0.45) | SLC18A3SIGMAR1AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL18639712 | 0.82 | HDAC2 (0.45) | SLC18A3SIGMAR1AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL15730212 | 0.82 | HDAC2 (0.45) | SLC18A3SIGMAR1AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL23868536 | 0.81 | PLG (0.41) | SLC18A3SIGMAR1PLGP2RY14 | |
| SCHEMBL30608334 | 0.81 | PLG (0.41) | PLGP2RY14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434522-A2 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4277895-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116964034-A | Heterocyclic ring P2Y 14 Receptor antagonists | 美国卫生和人力服务部 | 2023-10-27 | — | — | CN | disclosed |
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| WO-2022155037-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2008048053-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF PARKINSON'S DISEASE CONTAINING 1,2-DI[2-METHOXY-4-(2-CARBOXYLVINYL)]PHENOXYETHANE AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-04-24 | — | — | WO | disclosed |
| US-4353826-A | ANTITUBERCULAR ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | disclosed |
| US-4261891-A | BACTERICIDES, ANTITUBERCULAR AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| US-4005077-A | DERIVATIVES OF RIFAMYCIN S OR SV | CIBA-GEIGY CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY11 | SLC18A3 2012/4885SIGMAR1 285/4885PLG 3405/4885 |
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | SLC18A3 2438/4885SIGMAR1 1641/4885PLG 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.